Shenzhen Liying Bio-tech Co. , Ltd. recently completed a round of Zero Yuan Angel + financing. So far, only 12 months after its establishment, Shadowshade has completed two rounds of multi-million level financing. This round of financing by the New Vision Angel Fund LED investment, light bio-, Telmarine bio, Wuxi Best and other listed companies and dandelion venture capital investment and other institutions follow. This round of financing funds for the expansion of R & D team size, improve the core technology platform, large-scale pilot production site construction and market expansion.
Liying Biotech was founded in April 2022. Based on professional structural biology and cutting-edge artificial intelligence computing, Liying Bio focuses on protein modification and design, providing research and development services for different scenarios of protein applications. Liying Bio was successfully selected by the Shenzhen Engineering Biology Innovation Center and has been incubating in the Innovation Center for five months. As an innovation center, Liying Bio is the first enterprise to pass the incubation period and generate business income, shadowbiology has been the focus of many industrial capital and investment and financing institutions。
Liying Biotech is located in the Hengtaiyu synthetic biology industrial park of the Bright Science City, with a total area of 1,000 square meters, it has independent high-performance computing system, complete expression system from prokaryotic to eukaryotic, self-designed high-throughput protein purification screening facility, GMP-level recombinant protein purification and characterization laboratory.
Established 12 months ago, Liying Bio, as a technologically superior enterprise, is committed to breaking the long-standing monopoly of foreign brands in the protein raw materials industry, continuous focus on R & D optimization and import substitution of high-scarcity, high-threshold proteins, through the analysis of protein structure data and artificial intelligence prediction, using structural biology methods to precisely modify protein structures at the molecular level and at the source, and rapid screening by self-designed high-throughput protein purification platforms, to achieve the optimization of the function of protein iterations to obtain high-performance proteins.
Liying Biotech has established four core technology platforms: Artificial Intelligence platform for protein structure prediction, high-throughput structure biology platform, single B cell high performance antibody discovery platform, and protein pairwise screening and verification platform, has assisted in the development of more than 50 difficult protein raw materials, can be used in daily medical beauty, synthetic biology, enzyme engineering, in vitro diagnostic reagents, vaccine sequence design, protein macromolecule drugs, etc. , based on high-standard and high-quality R & D technology, to provide services for the whole synthetic biology and bio-medicine industry, and build an industrial eco-sphere。
Dr Ying Zhang, Chief Scientist of Liying Bio, said: “We are very grateful to the investors and entrepreneurs for their recognition and support of shadowbiology.”. Protein is the executive of life activities, is the most important and the most complex biomacromolecule, is the important foundation of the development of synthetic biology and bio-medicine industry, is also the source of innovation. Shadowbiology has always attached great importance to innovative R & D. This round of funding will help Liying's R & D capability to be enhanced and its R & D team to be built. Through building a sound artificial intelligence and high-throughput platform, it will accelerate the transformation of synthetic biotechnology and the advancement of research projects in progress, and empower the entire industry with high-level protein R & D. The smooth financing also reflects the industry experts and investors in the shadow of biological specialization, platform, innovation and future development potential of high recognition. Liying Bio will continue to work to create more value and contribute more to our investors, customers and industry.”
Dr Jun Chen, chairman of New Vision Angel, said: “The Zijin Capital team has always been committed to a sustainable ecological layout in the biomedical industry, and synthetic biology is a future field with disruptive and developmental potential.”. We have high hopes for Liying Bio's team of young, professorial scientists. We believe that Liying Bio will continue to leverage its innovative capabilities and technological advantages to achieve continuous transformation of scientific research results and bring more surprises and changes to the synthetic biology industry of the future.
Zhang Zhan, chairman of Weiguang bio, said: “Weiguang bio focuses on blood products, aiming at the innovation commanding heights and advanced models of the global bio-pharmaceutical industry, hoping to help more scientific research results translate into productivity.”. Liying Bio focuses on source-end technology innovation and has a founding team that has been working on cutting-edge fields for many years. Liying Bio has built a leading technology platform in the industry and believes that this financing will help the company achieve higher quality development.”
Zhai Liuwei, chairman of dimai Bio, said, “The development of dimai Bio benefits from Shenzhen's excellent industrial ecosystem and has witnessed the rapid development of many innovative and high-potential enterprises in the industry such as Liying Bio. Timai is looking forward to this investment to help outstanding entrepreneurs, scientists, along with the growth of shadowbiology. I believe that with the support of strong industry background and academic background, time will push Liying Bio to play its innovation advantages and constantly reflect its own value.”
Copyright © Shenzhen Liying Biotechnology Co., Ltd. All Rights Reserved. 粤ICP备2023053925号
